TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04698564
Drug: Hyperpolarized 13C-Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\].
Study: NCT00055471
Drug: ZD4054 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 10 mg oral tablets once daily
Study: NCT00055471
Drug: ZD4054 15 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 10 mg + 2 x 2.5 mg oral tablets once daily
Study: NCT00055471
Drug: ZD4054 22.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 10 mg + 2 x 2.5 mg oral tablets once daily
Study: NCT04613895
Drug: DWP14012
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 40 mg, orally, once daily just after a meal up to 4 weeks
Study: NCT04613895
Drug: DWP14012
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 40 mg, orally, once daily before a meal up to 4 weeks
Study: NCT04401527
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of Normal Saline
Study: NCT02787070
Drug: PQ supervised
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02787070
Drug: PQ unsupervised
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03366155
Drug: FUDR-Dex
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAIP will be filled with mixture of Floxuridine and Dexamethasone. Pump will perfuse drugs to liver for 14 days. Floxuridine (0.12 mg/kg X pump volume X pump flow rate),Dexamethasone (1 mg/day X pump volume (30) X pump flow rate)
Study: NCT03366155
Drug: 5FU
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000 mg/m2, IV 46-hour infusion of 5-Fluorouracil + 400 mg/m2, IV of Leucovorin
Study: NCT01931202
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert substance or treatment which is designed to have no therapeutic value but resemble the active medication in this study
Study: NCT01724320
Drug: OTX008
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTX008 given daily without interruption, subcutaneously. Starting dose: 65 mg/day
Study: NCT00028730
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00947765
Drug: Local corticosteroid injection
Normalized name: Corticosteroids acting locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were infiltrated with 2 milliliters of local corticosteroid (Methyl prednisolone acetate 80mg) mixed with 1 milliliters 0.5% Bupivacaine, at the lateral epicondyle according to the standard technique
Study: NCT01571297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given subcutaneously for 35 days
Study: NCT02524106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00818675
Drug: Comparator: Blinded Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four tablets of blinded placebo (to match ridaforolimus) administered daily for 5 consecutive days each week followed by 2 days of treatment holiday
Study: NCT00227656
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 twice daily during first 14 days of each 3-week cycle (2 weeks on, 1 week rest).
Study: NCT03959228
Drug: keto-analogs
Normalized name: Keto-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients that will be included in the experimental arm will have additional keto-analogs (1 pill/5 kg).
Study: NCT00043121
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00043121
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00043121
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT03955380
Drug: Contraloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of capsules, drug substance or placebo without any exipients.
Study: NCT02182960
Drug: Ibuprofen syrup
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03041805
Drug: LMWH
Normalized name: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin may be used after procedure by the decision of the doctor
Study: NCT00729365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dippers (category of subjects with a nighttime dip in blood pressure) will all be given Placebo. Control group.
Study: NCT00729365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into the control group and given Placebo.
Study: NCT04664829
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally twice a day. Dosage: 1000mg/m\^2
Study: NCT02547233
Drug: LEO 43204 gel
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02547233
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02175342
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02175342
Drug: Tiotropium-18 lactose powder
Normalized name: tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02175342
Drug: Placebo lactose powder
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03334916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 20mL TID
Study: NCT02537067
Drug: CHONDRON
Normalized name: Chondrus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Harvesting of ankle or knee cartilage~2. The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
Study: NCT03755700
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo of vitamin E as a soft gel capsule with the consumption order similar to vitamin e group
Study: NCT03755700
Drug: Normal Saline Flush, 0.9% Injectable Solution
Normalized name: Normal Saline Flush, 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization
Study: NCT00529568
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: double-blind matched placebo control daily oral administration
Study: NCT03600883
Drug: Anti PD-1/L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an intravenous (IV) infusion
Study: NCT01596673
Drug: 45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)
Normalized name: Hydrocodone Bitartrate Extended-Release Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase B:~Eligible subjects will be randomized to treatment sequence XY or YX whereby treatment X is 60 mL of a noncarbonated flavored beverage and treatment Y is hydrocodone bitartrate powder at a dose strength of 45-mg reconstituted in 60 mL of a noncarbonated flavored beverage.~Phase C:~Eligible subjects will be randomly assigned to 1 of 4 treatment arms:~Treatment A: intact placebo tablet, 60 mL noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment B: intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45-mg in 60 mL of a noncarbonated flavored beverage and 1 crushed placebo tablet.~Treatment C: intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet Treatment D: intact placebo tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet.
Study: NCT01596673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will consist of 60 mL of a non-carbonated beverage without the addition of active treatment
Study: NCT00217971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04138888
Drug: Olmesartan Medoxomil/Hydrochlorothiazide 40 Mg/25 Mg film-coated tablets for oral use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan Medoxomil/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
Study: NCT04138888
Drug: Olmetec® Plus 40 Mg/25 Mg film-coated tablets for oral use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmetec® Plus is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
Study: NCT00255801
Drug: Targretin® (bexarotene)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00255801
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02017379
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02017379
Drug: Metoclopromide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02112812
Drug: Eradication therapy for H.pylori infection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who were positive for H.pylori infection received an eradication therapy consisting of oral esomeprazole 40 md daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
Study: NCT02112812
Drug: Eradication of Helcobacter Pylori
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who are positive on urea breath test are given eradication therapy for 14 days, Eradication therapy includes esomeprazole 40mg daily, clarithromycin 500mg bd, amoxicillin 1g bd
Study: NCT02112812
Drug: Eradication therapy for Helicobacter pylori
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000512
Drug: lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
Study: NCT01472809
Drug: ZYGK1
Normalized name: Zygomycin K1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYGK1 Tablets: 0.125, 0.25, 0.5, 1, 2, .... mg.~Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved
Study: NCT03387592
Drug: CPT-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg/m2
Study: NCT03387592
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1500 mg/m2
Study: NCT01472809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablets: 0.125, 0.25, 0.5, 1, 2, ... mg
Study: NCT01743807
Drug: GNKG168
Approvals — FDA: no, EMA: no, PMDA: no
Description: GNKG168 will be given intravenously over 1 hour on days 1 through 5 followed by 9 days of rest. Dose will be assigned at study entry.~Dose Level 0: 0.15 mg/kg Dose Level 1: 0.25 mg/kg Dose Level 2: 0.75 mg/kg Dose Level 3: 1.5 mg/kg~The starting dose level for the trial will be 0.25 mg/kg. If that dose level proves to be intolerable, the dose will be reduced to 0.15 mg/kg (dose level 0). If the 0.15 mg/kg dose level is intolerable due to DLTs, TACL, the Principal Investigator, and Medical Monitor will then decide the best course of action for subsequent administration of GNKG168.
Study: NCT04036227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution with the same composition to match active drug
Study: NCT03435640
Drug: NKTR-262
Approvals — FDA: no, EMA: no, PMDA: no
Description: During Phase 1 Doublet: Patients receive escalating doses of NKTR-262 IT (starting dose 0.03 mg) in 3-week treatment cycles. During Phase 1 Doublet (Cohort A), Phase 2 Doublet: Patients were to receive the RP2D of NKTR-262.~During Phase 1 Triplet (Cohort B), and Phase 2 Triplet: Patients receive the RP2D of NKTR-262.
Study: NCT00619086
Drug: Dexamethason Helvepharm ®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg Dexamethason i.v. 45 minutes prior to surgery
Study: NCT00619086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml sodium chloride i.v. 45 minutes prior to surgery
Study: NCT03005379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule-delivered placebo
Study: NCT02165566
Drug: Regular-insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
Study: NCT04221087
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar water based on same ml dosing of intervention arm drug
Study: NCT05222243
Drug: Direct pulp capping with calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capping exposed dental pulps during cavity preparation in primary teeth with calcium hydroxide
Study: NCT05222243
Drug: Direct pulp capping with MTA
Normalized name: acai fruit pulp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capping exposed dental pulps during cavity preparation in primary teeth with MTA
Study: NCT03891953
Drug: DKY709
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel immunomodulatory agent
Study: NCT03891953
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2
Study: NCT01935869
Drug: LEO 90100
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01812889
Drug: TOL-463 Vaginal ovule
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOL-463 Vaginal Ovule
Study: NCT04246801
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
Study: NCT04401748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; Oral
Study: NCT03038178
Drug: LAI plus multi-drug regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal Amikacin for Inhalation (LAI) is the experimental treatment which, in this single arm will be taken in conjunction with standard of care multi-drug treatment regimen
Study: NCT02595528
Drug: AGN-199201 ophthalmic solution
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
Study: NCT02595528
Drug: AGN-190584 ophthalmic solution
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye.
Study: NCT02595528
Drug: AGN-190584 vehicle
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle to AGN-190584
Study: NCT02595528
Drug: AGN-199201 + AGN-190584 Combination
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye.
Study: NCT02595528
Drug: AGN-199201 vehicle
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle to AGN-199201
Study: NCT00237328
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin will be used as the intra-operative anticoagulant
Study: NCT00833547
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules looking identical to eszopiclone at bedtime on two consecutive nights
Study: NCT01690520
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04165330
Drug: AL3818
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL3818: Part 1 - 12 mg, 10 mg, 8 mg, or 6 mg (by dosing cohort), Part 2 - RP2D (as determined from Part 1).~Administered orally once daily on Days 1-14 per 21 day Cycle.
Study: NCT00096382
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg/day x 2 days intravenously over 1 hour
Study: NCT00929812
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml NaCl 0.9% intramuscularly
Study: NCT04468659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion.
Study: NCT03190954
Drug: [11C]NNC-112
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[11C\]NNC-112 PET scan obtained without any drug intervention to measure dopamine D1 receptors. Blind N/A
Study: NCT05504317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive corresponding dose of placebo injection subcutaneously.
Study: NCT02133521
Drug: DLBS1033
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
Study: NCT02133521
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
Study: NCT03396393
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT02236754
Drug: 18 F-FP-DTBZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug, no carrier added \[18 F\]-FP-DTBZ, is formulated in 5% (v/v) ethanol in 0.9% sterile saline solution to produce \[18 F\]-FP-DTBZ for injection. Subjects will receive a single i.v. administration of no more than 7.6 millicuries (mCi) of \[18 F\]-FP-DTBZ for injection immediately prior to imaging. The specific activity at time of injection will less than 1.0 mCi/microgram and thus for a 7.6 mCi dose the maximal mass dose will be less than 10 microgram.
Study: NCT03182920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT04351191
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care plus placebo
Study: NCT02343133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02858856
Drug: Sipjeondaebo-tang
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Herbal medicine which is a compound of 10 herbs.
Study: NCT03273127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abediterol matching placebo without any pharmacological activity.
Study: NCT00865982
Drug: Docetaxel, Cisplatin, Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 preoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks~followed by resection~and 3 postoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks.
Study: NCT04146220
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients of the low and the high dose groups recieved prednisolone in different dose for initial 4 weeks, then tapered gradually. Both groups received pulse I/V methylprednisolone 500 mg/day daily for initial 3 days and monthly cyclophosphamide infusion 750-1000 mg/m2 body surface area.
Study: NCT02784860
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the placebo group, the same volume of normal saline is administered after loss of consciousness
Study: NCT02667496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study: NCT00955279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
Study: NCT00961753
Drug: optimized ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: day of life 0-3 - 10, 5, 5 mg/kg/dose at 24 hour intervals day of life 4-6 - 14, 7, 7 mg/kg/dose at 24 hour intervals day of life 7-29 - 20, 10, 10 mg/kg/dose at 24 hour intervals
Study: NCT04411628
Drug: LY3819253
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT04411628
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT04607603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered in capsules of identical appearance to CBD capsules in 3 doses per die
Study: NCT02844179
Drug: HTBZ
Normalized name: Hypertebain
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00225303
Drug: TMC125
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03584152
Drug: Norco 5Mg-325Mg Tablet
Normalized name: Norco 5mg-325mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid Analgesics
Study: NCT03584152
Drug: Tylenol 325Mg Caplet
Normalized name: Tylenol 325mg Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non opioid analgesics
Study: NCT03584152
Drug: Ibuprofen 200 mg
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Non opioid analgesics
Study: NCT00950599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, once daily, 6 and 12 weeks
Study: NCT03858634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dose administered via 2 SC injections within 30 minutes on Day 1. All subsequent doses of placebo administered via a single SC injection.